title: Targeting microRNAs to limit myocardial lipid accumulation.
authors.affiliation: From the Cardiovascular Translational Science Institute (G.D.L., J.R.U.) and Faculty of Pharmacy and Pharmaceutical Sciences (J.R.U.), University of Alberta, Edmonton, Canada. gary.lopaschuk@ualberta.ca.
authors.forename: Gary D
authors.initials: GD
authors.lastname: Lopaschuk
authors.affiliation: From the Cardiovascular Translational Science Institute (G.D.L., J.R.U.) and Faculty of Pharmacy and Pharmaceutical Sciences (J.R.U.), University of Alberta, Edmonton, Canada.
authors.forename: John R
authors.initials: JR
authors.lastname: Ussher
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000818:Animals; D006332:Cardiomegaly / Q000378:metabolism*; D059305:Diet, High-Fat / Q000009:adverse effects*; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D035683:MicroRNAs; C550758:Mirn451 microRNA, mouse; D017346:Protein Serine-Threonine Kinases; C491654:Stk11 protein, mouse; D055372:AMP-Activated Protein Kinases
keywords: AMP-activated protein kinases; Editorials; cardiomyopathies; ceramides; heart; microRNA; obesity